Novo Nordisk – Global Leader in Diabetes and Obesity Care
Novo Nordisk
Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, near Copenhagen. It was formed in 1989 through the merger of two Danish insulin makers, Nordisk Insulinlaboratorium (founded in 1923) and Novo Terapeutisk Laboratorium (1925). Its shares are listed on Nasdaq Copenhagen and its American depositary receipts on the New York Stock Exchange. Most of the voting rights are held by Novo Holdings, which is wholly owned by the Novo Nordisk Foundation.
The company's main areas are diabetes and obesity. Novo Nordisk makes insulins and delivery devices, as well as medicines for haemophilia and other bleeding disorders, growth hormone and hormone replacement therapy.
Its growth in recent years has been driven above all by semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Products based on it include Ozempic, a once-weekly injection for type 2 diabetes (approved in the US in 2017); Rybelsus, the first GLP-1 receptor agonist in tablet form (2019); and Wegovy for weight loss and weight management — first as an injection (2021) and, since December 2025 in the US, also as a tablet.
Unifarm carries Novo Nordisk's semaglutide medicines: Ozempic 1 (pre-filled pen), Rybelsus 3, 4, 7, 9 and 14 (tablets) and Wegovy 1.5, 4, 9 and 25 (tablets).